About Victory Pharma, Inc.
Victory was founded in 2003 by an experienced management team that has previously built other successful specialty pharmaceutical companies. Over time, Victory has acquired a series of pain management products which we currently market to rheumatologists, orthopedists, pain specialists and selected primary care physicians. At Victory, our experienced sales representatives use their knowledge of pain and related conditions as a resource to support healthcare professionals in tailoring pain solutions to the needs of individual patients.
Our lead product is NAPRELAN®, a non-steroidal anti-inflammatory drug (NSAID) acquired in late 2006. NAPRELAN, the only branded, once-daily naproxen sodium product on the market, contains the gold standard NSAID. With the well-publicized cardiovascular toxicity concerns regarding COX-2 inhibitors, the treatment paradigm is shifting back to traditional NSAID therapies. NAPRELAN is well positioned for this shift, as it has the lowest NSAID-associated cardiovascular risk.(1,2) It also has a patent-protected delivery system that may minimize the GI irritation seen with NSAID therapies among certain patients.(3) We have significantly increased NAPRELAN sales since its re-launch in January 2007, and we believe that NAPRELAN is poised for further growth. We recently launched two additional strengths of NAPRELAN, providing physicians with greater titration flexibility for the treatment of pain.
In addition to acquiring and marketing pain relief products, we have also established a development pipeline focused on meeting current challenges in pain management and related conditions. These development programs will be NDA submissions utilizing the FDA 505(b)(2) pathway and involve novel formulations, alternative delivery forms and patented combinations of prescription products that have already received U.S. regulatory approval. This development approach significantly reduces development time, cost and risk.
For more information on Victory Pharma, Inc., please visit www.victorypharma.com.
Please see our Privacy Statement.
References:
1. McGettigan, P, Henry, D. Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA. 2006; 296: 1633-1644
2. Salpeter, S.R., Gregor, P., Ormiston, T., et al. Meta-Analysis: Cardiovascular Events Associated with Nonsteroidal Anti-inflammatory Drugs, The American Journal of Medicine 2006; 119: 552-559
3. NAPRELAN® Prescribing Information, San Diego, CA, Victory Pharma Inc. 2007
Victory was founded in 2003 by an experienced management team that has previously built other successful specialty pharmaceutical companies. Over time, Victory has acquired a series of pain management products which we currently market to rheumatologists, orthopedists, pain specialists and selected primary care physicians. At Victory, our experienced sales representatives use their knowledge of pain and related conditions as a resource to support healthcare professionals in tailoring pain solutions to the needs of individual patients.
Our lead product is NAPRELAN®, a non-steroidal anti-inflammatory drug (NSAID) acquired in late 2006. NAPRELAN, the only branded, once-daily naproxen sodium product on the market, contains the gold standard NSAID. With the well-publicized cardiovascular toxicity concerns regarding COX-2 inhibitors, the treatment paradigm is shifting back to traditional NSAID therapies. NAPRELAN is well positioned for this shift, as it has the lowest NSAID-associated cardiovascular risk.(1,2) It also has a patent-protected delivery system that may minimize the GI irritation seen with NSAID therapies among certain patients.(3) We have significantly increased NAPRELAN sales since its re-launch in January 2007, and we believe that NAPRELAN is poised for further growth. We recently launched two additional strengths of NAPRELAN, providing physicians with greater titration flexibility for the treatment of pain.
In addition to acquiring and marketing pain relief products, we have also established a development pipeline focused on meeting current challenges in pain management and related conditions. These development programs will be NDA submissions utilizing the FDA 505(b)(2) pathway and involve novel formulations, alternative delivery forms and patented combinations of prescription products that have already received U.S. regulatory approval. This development approach significantly reduces development time, cost and risk.
For more information on Victory Pharma, Inc., please visit www.victorypharma.com.
Please see our Privacy Statement.
References:
1. McGettigan, P, Henry, D. Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA. 2006; 296: 1633-1644
2. Salpeter, S.R., Gregor, P., Ormiston, T., et al. Meta-Analysis: Cardiovascular Events Associated with Nonsteroidal Anti-inflammatory Drugs, The American Journal of Medicine 2006; 119: 552-559
3. NAPRELAN® Prescribing Information, San Diego, CA, Victory Pharma Inc. 2007
©2007-2009 Victory Pharma, Inc. All Rights Reserved. 1-866-427-6819
